The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction (American patent application No: 17/255,264; NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in the US at least until 2039. Patents have previously been granted by the European Patent Office (EPO) and also in Japan, South Africa and Canada.

For more information:
Mia Lundblad, CEO
Arcede Pharma AB
mia.lundblad@arcedepharma.com
+46 723 12 27 44

The information was submitted for publication on March 15, 2023.

About Arcede Pharma
Arcede Pharma is aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients. Chronic obstructive pulmonary disease (COPD) is a disease that has a substantial negative impact on patients and causes a lot of suffering. COPD is the third most common cause of death worldwide. For more information: www.arcedepharma.com